C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Since June 2019, under the umbrella of the national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests. The Ministry of Health, Labour and Welfare (MHLW) of Japan constructed a network of CGM hospitals (a total of 233 institutes as of July 1, 2022) and established the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), the national datacenter for CGM. Clinical information and genomic data from the CGP tests are securely transferred to C-CAT, which then generates “C-CAT Findings” reports containing information of clinical annotation and matched clinical trials based on the CGP data. As of June 30, 2022, a total of 36,340 datapoints of clinical/genomic information are aggregated in C-CAT, and the number is expected to increase swiftly. The data are now open for sharing with not only the CGM hospitals but also other academic institutions and industries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867 · cited 1×
“6%) BRAF mutation (6) EGFR mutation (3) ALK fusion (1) BRAF fusion (11) FGFR1 fusion (1) FGFR2 fusion (3) ERBB2 fusion (1) NRG1 fusion (1) NTRK1 fusion (1) RAF1 fusion (2) RET fusion (2) ERBB2 amplification (15) MDM2 amplification (3)”
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
ClinVar: improvements to accessing data
Landrum, M. J., Chitipiralla, S., Brown, G. R., Chen, C., Gu, B., Hart, J., Hoffman, D., Jang, W., Kaur, K., Liu, C., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz972 · Cited by 994
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos, A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3774 · Cited by 628
Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210 · cited 1×
“Researchers can, for instance, readily identify in the C-CAT data compound mutations within EGFR in lung cancer positive for EGFR(L858R) that failed to respond to EGFR inhibitors (25, 26).”
Self-citation
Cited by
Harnessing Real-World Evidence to Advance Cancer Research
Tang, M., Pearson, S.-A., Simes, R. J., & Chua, B. H. (2023) · Current Oncology · doi:10.3390/curroncol30020143 · Cited by 88
Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010235 · Cited by 11
“…the SHIZUKU-HN study aims to evaluate the potential of ctDNA as a real-time biomarker for monitoring treatment response in HNSCC patients undergoing ICI therapy, using data from Japan’s national genome database established by the Cancer Center for Advanced Cancer Genome Therapy (C-CAT) [11,12].”
Metadata
- Authors
- Kohno, T., Kato, M., Kohsaka, S., Sudo, T., Tamai, I., Shiraishi, Y., Okuma, Y., Ogasawara, D., Suzuki, T., Yoshida, T., & Mano, H.
- Venue
- Cancer Discovery
- Published
- 2022-11-02
- Volume
- 12
- Issue
- 11
- Pages
- 2509-2515
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4307861905
- Cited by
- 214
- References
- 5
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.